Navigation Links
Rutgers research tackles childhood epilepsy
Date:6/10/2009

NEW BRUNSWICK, N.J. Rutgers researchers have discovered a potential new way to treat childhood epilepsy using a widely available therapeutic drug.

Rutgers neuroscientist Gabriella D'Arcangelo and her colleagues have published their research findings in the journal Disease Models and Mechanisms (in press) and the paper has just appeared online.

In their quest for new therapeutic approaches, the researchers are investigating the molecular basis of the disease. The article describes the first use of a mouse model of cortical dysplasia, a malformation of the brain that is most often the cause of childhood epilepsy. Introducing the drug rapamycin, originally used to prevent rejection in organ transplants, suppressed epileptic seizures in the mice.

Epilepsy is the third most common neurological disorder in the United States after Alzheimer's disease and stroke. It currently affects more than 326,000 children under age 15. More than 90,000 of them have severe seizures that cannot be adequately treated. The children often go on to develop cognitive problems due to recurrent and uncontrolled seizures and the combined effects of heavy medication. They may also suffer consequences from having parts of their brains removed during surgery.

According to the International League Against Epilepsy (ILAE), approximately 45 percent of the pediatric epilepsy surgery cases (patients under age 18) are due to cortical dysplasia. A staggering 75 percent of surgery patients under age 2 have the condition.

"The surgery is not without risks, and while it may help control the seizures, it does not work in all cases," said D'Arcangelo, an associate professor in the Department of Cell Biology and Neuroscience at Rutgers, The State University of New Jersey. "Clearly there is a pressing need to come up with new strategies for treatment."

D'Arcangelo's mutant mice lack a gene (Pten) that suppresses cell growth in some neurons, resulting in these mutants displaying molecular, cellular and physiological traits of cortical dysplasia. The researchers treated the mice with rapamycin. It had already shown promise in a different mouse model for treating tuberous sclerosis complex (TSC), a subtype of cortical dysplasia.

"We demonstrated that rapamycin is a novel and effective anti-epileptic agent that suppresses seizures in our mice, as well as in the TSC model, and this has raised some hope for the future," said D'Arcangelo. "This drug is being tested on human patients of tuberous sclerosis in a multicenter study involving six TSC clinics throughout the United States. I hope it will soon be tested for all cortical dysplasia patients."


'/>"/>

Contact: Joseph Blumberg
blumberg@ur.rutgers.edu
732-932-7084 x652
Rutgers University
Source:Eurekalert  

Related biology news :

1. Rutgers study finds many consumers ignore food product recalls
2. Evolution and climate change research advances at Rutgers-Camden
3. Rutgers receives US$10 million to establish Institute for Food, Nutrition and Health
4. Rutgers scholar authors definitive biography of reproductive medicine pioneer
5. No helicopter moms among Rutgers mutant mice
6. $3.2M for Rutgers to apply biology, engineering, physical sciences toward stem cells
7. Rutgers biologist to study worms in Amazon, glaciers
8. Better protection for biomedial devices could result from Rutgers-Camden research
9. Raydiance collaborates with Rutgers, MTF to develop innovative tissue processing approaches
10. USDA Cooperative Agreement funds mosquito project at Rutgers
11. Rutgers scientists research reveals critical knowledge about the nervous system
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Rutgers research tackles childhood epilepsy
(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... The global synthetic-biology ... $11.4 billion by 2021, growing at a compound annual growth ... An overview of the global markets for synthetic biology. - ... for 2016, and projections of compound annual growth rates (CAGRs) ...
(Date:2/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... will present at the LEERINK Partners 6th Annual Global ... on Wednesday, February 15, 2017 at 10 a.m. Eastern ... presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  The ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
Breaking Biology News(10 mins):
(Date:2/21/2017)... ... February 21, 2017 , ... During ... connected digital health applications, announced a partnership with Redox, a leader in cloud-based ... to many clinical systems while keeping data secure in the cloud. , The ...
(Date:2/21/2017)... ... February 21, 2017 , ... With ... operational capacity with its strategic internal leadership to provide clients with best ... operational management. With office locations in North Carolina, Massachusetts, Ohio, Illinois, ...
(Date:2/21/2017)... , Feb. 21, 2017   Logicalis Healthcare Solutions ... IT solutions and managed services provider ( www.us.logicalis.com ), ... Desk for Epic. The new service will help hospital ... resources by giving physicians, nurses and other clinicians immediate ... tier-one support. This will allow hospital IT staff to ...
(Date:2/20/2017)... - BioAmber Inc. (NYSE: BIOA ) announced today that Jean-Francois ... the company,s COO, has been named President, effective immediately.  ... Fabrice has overseen the construction, start-up and operation of the manufacturing ... the Mitsui JV.  Fabrice has also been extensively involved in the ... ...
Breaking Biology Technology: